ArticleFrontiers in medicine2025
KLF4 orchestrates a Ccl2+ fibroblast-mediated inflammatory network driving preterm birth.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preterm birth (PTB) remains the leading cause of neonatal mortality and long-term complications, yet its molecular mechanisms are incompletely understood. Fibroblasts, as critical components of the gestational microenvironment, have an undefined role in PTB pathogenesis. Methods: This study employed single-cell RNA sequencing (scRNA-seq) datasets from murine preterm birth models (GSE200289 and E-MTAB-11491), processed using Seurat and Harmony for clustering and integration, to analyze cellular heterogeneity. This was integrated with Mendelian randomization (MR) using eQTLs from FinnGen and IEU GWAS databases as instrumental variables, and validated through functional experiments including LPS-induced placental explant cultures, qRT-PCR, western blotting, immunohistochemistry, and an Results: We first established a single-cell transcriptomic atlas of preterm mice, identifying nine cell clusters, among which the Ccl2+ fibroblast subpopulation (Ccl2+fib) exhibited significant expansion under pathological conditions. MR analysis identified KLF4 as a genetic risk factor for PTB (OR = 1.32, 95% CI: 1.12-1.56), with reverse MR confirming the absence of reverse causality. Clinical validation revealed KLF4-specific upregulation in peripheral blood and placental tissues of PTB patients. Functional studies demonstrated dose-dependent KLF4 upregulation in LPS-induced placental inflammation, while KLF4 knockdown suppressed TNF-α and IL-1β secretion and reduced apoptosis. In a rat intrauterine infection model, KLF4 knockdown decreased LPS-induced preterm birth rates from 65% to 20%, accompanied by significantly reduced fetal stillbirth rates. Conclusion: This study reveals that the fibroblast subpopulation Ccl2+fib contributes to preterm birth through a KLF4-dependent inflammatory regulatory network. KLF4 downregulation significantly reduces infection-induced preterm birth rates and adverse pregnancy outcomes, suggesting that KLF4 is a critical therapeutic target for preterm birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.